317 results
Page 2 of 16
8-K
EX-4.1
i7qxtw2qy77 7zlbyxx3
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
9n2dfd j5kf3o
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
EX-10.1
mqkrsjmgt8eqk
19 May 23
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-1.1
xgvw1n 3s0f
12 May 22
Entry into a Material Definitive Agreement
8:31am
424B5
ixrejsjgmme7ml0np68
12 May 22
Prospectus supplement for primary offering
8:30am
8-K
EX-10.1
2q48it9 5ymtty
10 Jan 22
Departure of Directors or Certain Officers
4:28pm
8-K
EX-10.2
ucc672jy8dlvofsd j5
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-99.1
n5vq1btgf0
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.2
4p8rz45dqyqa 2ofuy5
24 Nov 21
Entry into a Material Definitive Agreement
7:27am